196 related articles for article (PubMed ID: 33691532)
1. Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.
Tuohy JL; Byer BJ; Royer S; Keller C; Nagai-Singer MA; Regan DP; Seguin B
Vet Pathol; 2021 May; 58(3):516-526. PubMed ID: 33691532
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience.
Morotti RA; Nicol KK; Parham DM; Teot LA; Moore J; Hayes J; Meyer W; Qualman SJ;
Am J Surg Pathol; 2006 Aug; 30(8):962-8. PubMed ID: 16861966
[TBL] [Abstract][Full Text] [Related]
3. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of New Monoclonal Anti-MyoD1 (MX049) for the Diagnosis of Rhabdomyosarcoma: Comparison with 5.8A, EP212, Anti-Desmin, Anti-Myogenin, and Fluorescence
He Y; Chen X; Yu X
Ann Clin Lab Sci; 2020 May; 50(3):412-416. PubMed ID: 32581037
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma.
Cui S; Hano H; Harada T; Takai S; Masui F; Ushigome S
Pathol Int; 1999 Jan; 49(1):62-8. PubMed ID: 10227726
[TBL] [Abstract][Full Text] [Related]
7. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood.
Wang NP; Marx J; McNutt MA; Rutledge JC; Gown AM
Am J Pathol; 1995 Dec; 147(6):1799-810. PubMed ID: 7495304
[TBL] [Abstract][Full Text] [Related]
8. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
[TBL] [Abstract][Full Text] [Related]
9. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
10. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
Rekhi B; Dodd L; Dharavath B; Dutt A
Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
[TBL] [Abstract][Full Text] [Related]
11. Invasive spindle-cell rhabdomyosarcoma with osteolysis in a dog: case report and literature review.
Shi J; Gao R; Zhang J; Xu R; Jia Q; Ma Y; Lu H; Zhao K; Gao F; He W
J Vet Diagn Invest; 2023 Mar; 35(2):168-172. PubMed ID: 36600502
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to desmin identify the blastemal component of nephroblastoma.
Folpe AL; Patterson K; Gown AM
Mod Pathol; 1997 Sep; 10(9):895-900. PubMed ID: 9310952
[TBL] [Abstract][Full Text] [Related]
13. [Spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological study of 20 cases].
Yang L; Zhang HJ; Yang SJ
Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):336-342. PubMed ID: 32268670
[No Abstract] [Full Text] [Related]
14. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma.
Fine SW; Lisanti MP; Argani P; Li M
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):231-6. PubMed ID: 16082247
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: a Children's Oncology Group study.
Nicol K; Savell V; Moore J; Teot L; Spunt SL; Qualman S;
Pediatr Dev Pathol; 2007; 10(2):89-97. PubMed ID: 17378682
[TBL] [Abstract][Full Text] [Related]
16. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
[TBL] [Abstract][Full Text] [Related]
17. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
[TBL] [Abstract][Full Text] [Related]
18. A new human pleomorphic rhabdomyosarcoma cell-line, HS-RMS-1, exhibiting MyoD1 and myogenin.
Sonobe H; Takeuchi T; Taguchi T; Shimizu K; Furihata M; Ohtsuki Y
Int J Oncol; 2000 Jul; 17(1):119-25. PubMed ID: 10853028
[TBL] [Abstract][Full Text] [Related]
19. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical profile of myogenin and MyoD1 does not support skeletal muscle lineage in alveolar soft part sarcoma.
Gómez JA; Amin MB; Ro JY; Linden MD; Lee MW; Zarbo RJ
Arch Pathol Lab Med; 1999 Jun; 123(6):503-7. PubMed ID: 10383802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
